As CEO of Medicines360, Andrea Olariu leads the organization in its mission to expand access to health innovations for all women from day one. She established the organization’s groundbreaking 360 Innovation Hub to identify and address critical health gaps for women, in order to bring needed innovations to women everywhere.

Since joining Medicines360 in 2010, Andrea has held several key roles within the organization. She oversaw the development program for Medicines360’s first product, a hormonal intrauterine device (IUD), that included the largest and most diverse U.S. Phase 3 clinical study ever on an IUD. This work catalyzed broader access to the IUD for all women and especially the underserved. Following FDA approval of the IUD in 2015, Andrea led the strategy to further extend the IUD’s duration of use and to make it available in several low- and middle-income countries.

Andrea is a medical doctor specializing in dermatology and venerology with a PhD in Immunology, who started her career in academia. She was previously Associate Professor of Dermatology at the University of Szeged in Szeged, Hungary and Senior Lecturer of Immunology at the Victor Babes University of Medicine and Pharmacy in Timisoara, Romania.

Prior to joining Medicines360, Andrea developed and implemented clinical and regulatory strategies for medical devices that received approval in the United States, Canada, and European Union. Andrea’s commitment to women’s health is shaped by her upbringing in Romania when human rights and access to health care, particularly for women, was very limited.  

Andrea has authored more than 40 peer-reviewed medical publications, is the recipient of several academic honors, and has spoken at national and international conferences.